Marshall Urist, EVP of Royalty Pharma RPRX, has filed 0 purchases and 16 sales on the open market. Over the past 12 months that comes to a net sale of $11.6M. The latest trade was on 06/24.

MU

MU

Marshall Urist

EVP, Research & Investments

Company

Royalty Pharma RPRX

First filing

23/02/17

Trades

28 trades

Buys / sales

0 / 16

12-month net buying

−$11.6M

Last trade

06/24

FollowShare

Trading activity

6 months1 year2 years5 yearsAll

Transactions

Company	Trade type	Traded	Filed	Shares	Price	Value	Holding change
Royalty PharmaRPRX	Open-market sale10b5-1 plan	06/24	06/25	9,098 sh	$55.18	$502,027.64	−50.0%
Royalty PharmaRPRX	Open-market sale10b5-1 plan	05/20	05/21	13,684 sh	$52.75	$721,831	−42.9%
Royalty PharmaRPRX	Open-market sale10b5-1 plan	05/14	05/15	13,684 sh	$53.06	$726,073.04	−30.0%
Royalty PharmaRPRX	Open-market sale10b5-1 plan	01/30	02/02	20,000 sh	$41.09	$821,800	−100.0%
Royalty PharmaRPRX	Open-market sale10b5-1 plan	01/23	01/26	20,000 sh	$40.26	$805,200	−50.0%
Royalty PharmaRPRX	Open-market sale10b5-1 plan	01/16	01/20	20,000 sh	$39.52	$790,400	−33.3%
Royalty PharmaRPRX	Open-market sale10b5-1 plan	01/09	01/13	20,000 sh	$40.78	$815,600	−25.0%
Royalty PharmaRPRX	Open-market sale10b5-1 plan	01/02	01/06	20,000 sh	$38.48	$769,600	−20.0%
Royalty PharmaRPRX	Open-market sale10b5-1 plan	25/12/26	25/12/29	20,000 sh	$39.32	$786,400	−16.7%
Royalty PharmaRPRX	Open-market sale10b5-1 plan	25/12/19	25/12/22	20,000 sh	$38.38	$767,600	−14.3%
Royalty PharmaRPRX	Open-market sale10b5-1 plan	25/12/16	25/12/17	20,000 sh	$38.32	$766,400	−12.5%
Royalty PharmaRPRX	Open-market sale10b5-1 plan	25/12/05	25/12/09	41,576 sh2 trades	$39.15avg.	$1,627,700.4	No record
Royalty PharmaRPRX	Open-market sale10b5-1 plan	25/12/01	25/12/03	41,575 sh2 trades	$39.92avg.	$1,659,542.49	No record
Royalty PharmaRPRX	Open-market sale	23/02/22	23/02/24	23,333 sh	$37.30	$870,320.9	−33.3%